Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Cerus Corp Chief Financial Officer Kevin Dennis Green reported two stock transactions involving the company’s common shares. He sold 33,676 shares at a weighted average price of about $2.94 per share under a pre-set Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees tied to restricted stock unit vesting, which the footnote explains was not a discretionary sale.
On the same date, he also acquired 63,600 shares through a grant or award at no cost. Following these transactions, he directly holds 1,062,188 shares of Cerus common stock.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported a mix of equity grants and a tax-related share sale. He received 554,529 shares of common stock as an equity award and 369,686 performance rights, each tied to one share of common stock.
The common stock award vests in two annual installments, with 33% vesting on July 1, 2027 and 67% on July 1, 2028, contingent on continued service. The performance rights vest only if Cerus stock reaches a specified price per share.
On June 30, 2026, he sold 42,359 shares of common stock at a weighted average price of $2.9429 per share under a pre-set Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees, described as non-discretionary. After these transactions, he directly holds 2,248,877 common shares and 369,686 performance rights.
CERUS CORP Chief Legal Officer Chrystal Jensen reported two common stock transactions. On June 30, 2026, Jensen sold 24,329 shares of common stock at a weighted average price of $2.9429 per share. According to the disclosure, these shares were sold under an instruction intended to comply with Rule 10b5-1 to cover statutory tax withholding obligations and related brokerage fees tied to vesting restricted stock units, and did not represent a discretionary sale.
On the same date, Jensen also acquired 55,000 shares of common stock as a grant or award at no cost. Following these transactions, Jensen directly held 966,657 shares of CERUS CORP common stock.
CERUS CORP President and CEO William Mariner Greenman reported a mix of tax-related sales and equity compensation grants in company stock. He sold 101,919 shares of common stock at a weighted average price of $2.94 per share under a pre-arranged Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees tied to vesting restricted stock units, which the disclosure notes was not a discretionary sale. He also received a grant or award of 192,500 shares of common stock at no cost. Following these transactions, he directly holds 5,053,036 shares of CERUS common stock.
Cerus Corp director Eric Bjerkholt sold shares in an open-market transaction. On this trade, he sold 20,454 shares of Cerus common stock at a price of $2.60 per share. After the sale, he directly owned 261,679 shares of the company’s common stock.
Cerus Corporation entered into new secured credit agreements that refinance and expand its debt facilities. The term loan agreement provides up to $65.0 million, of which $35.0 million was drawn on closing to refinance existing term loans, after having repaid $30.0 million under the prior term facility. An additional $30.0 million term tranche may be requested in minimum $5.0 million increments for working capital and general corporate purposes.
The revolving credit agreement provides an initial $30.0 million borrowing base-driven revolver, with potential to increase commitments by $15.0 million. As of the closing date, $29.9 million was outstanding. Term loans bear interest at Term SOFR plus 5.50%, and revolver borrowings at Term SOFR plus 3.70%, each with a 1.00% SOFR floor. Cerus’s obligations are secured by substantially all assets and are subject to revenue-based financial covenants and customary negative covenants and events of default.
Cerus Corporation reported results from its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2024 Equity Incentive Plan, increasing the common stock available for issuance under the plan by 10,000,000 shares.
Stockholders also elected William M. Greenman and Ann Lucena to the board to serve until the 2029 Annual Meeting. In additional votes, shareholders approved on an advisory basis the compensation of named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Lucena Ann reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Ann Lucena received a grant of 60,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one share. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to her continuous service. Following this award, she holds 232,284 shares directly.
Cerus Corp director Eric Bjerkholt received an equity grant rather than buying shares on the market. He was awarded 60,000 shares of common stock in the form of restricted stock units (RSUs) under Cerus’ 2024 Equity Incentive Plan at no cash cost.
Each RSU converts into one share of common stock if it vests. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as he continues to serve the company. After this grant, he directly holds 282,133 shares.